1. Scrip

Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar

Ustekinumab, Denosumab And Pertuzumab Biosimilars Progress

 
• By Anju Ghangurde

Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”

Humira Biosimilars Line Up: Does Interchangeability Matter? • Source: Shutterstock

Biocon, Ltd. fielded a range of questions on the upcoming opportunity for its biosimilar to AbbVie Inc.’s Humira (adalimumab) at its quarterly earnings discussion, with senior management indicating that interchangeability isn’t likely to be a defining factor to win in the US market.

Shreehas Tambe, CEO and managing director, Biocon Biologics Ltd (BBL), said the firm’s partnered adalimumab biosimilar, sold as Hulio in Europe, “checks the key boxes” of being both citrate and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

 
• By Jung Won Shin

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.